Multi-functional nanocarriers to overcome tumor drug resistance

被引：361

作者：

Jabr-Milane, Lara S. ^{[1
]}

van Vlerken, Lilian E. ^{[1
]}

Yadav, Sunita ^{[1
]}

Amiji, Mansoor M. ^{[1
]}

机构：

[1] Northeastern Univ, Sch Pharm, Dept Pharmaceut Sci, Boston, MA 02115 USA

来源：

CANCER TREATMENT REVIEWS | 2008年 / 34卷 / 07期

关键词：

Multi-drug resistance; Multi-functional nanocarriers; Drug delivery; Resistance modulators; Energy delivery;

D O I：

10.1016/j.ctrv.2008.04.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers; specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance modulators (e.g., with P-glycoprotein substrates), agents that regulate intracellular pH, agents that tower the apoptotic threshold (e.g., with ceramide), or in combination with energy delivery (e.g., sound, heat, and tight) to enhance the effectiveness of anticancer agents in refractory tumors. In preclinical studies, the use of multi-functional nanocarriers has shown significant promise in enhancing cancer therapy, especially against MDR tumors. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：592 / 602

页数：11

共 84 条

[11]

Dogliotti L, 1995, Minerva Endocrinol, V20, P105

[12]

ELIAS A D, 1992, Current Opinion in Oncology, V4, P681, DOI 10.1097/00001622-199208000-00013

[13] Sphingosine, a product of ceramide hydrolysis, influences the formation of ceramide channels [J].

Elrick, Matthew J. ;

Fluss, Sharon ;

Colombini, Marco .

BIOPHYSICAL JOURNAL, 2006, 91 (05) :1749-1756

[14] Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy [J].

Fisker, Niels ;

Westergaard, Majken ;

Hansen, Henrik Frydenlund ;

Hansen, Jens Bo .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2007, 26 (10-12) :1427-1430

[15] Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization [J].

Fretz, Marjan M. ;

Hogset, Anders ;

Koning, Gerben A. ;

Jiskoot, Wim ;

Storm, Gert .

PHARMACEUTICAL RESEARCH, 2007, 24 (11) :2040-2047

[16]

Gaber Mohamed H, 2002, J Biochem Mol Biol Biophys, V6, P309, DOI 10.1080/10258140290033066

[17] Chemotherapy-induced resistance by ATP-binding cassette transporter genes [J].

Gillet, Jean-Pierre ;

Efferth, Thomas ;

Remacle, Jose .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2007, 1775 (02) :237-262

[18] Multidrug resistance in cancer: Role of ATP-dependent transporters [J].

Gottesman, MM ;

Fojo, T ;

Bates, SE .

NATURE REVIEWS CANCER, 2002, 2 (01) :48-58

[19] Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs [J].

Gouazé, V ;

Liu, YY ;

Prickett, CS ;

Yu, JY ;

Giuliano, AE ;

Cabot, MC .

CANCER RESEARCH, 2005, 65 (09) :3861-3867

[20] Ceramide and cell death receptor clustering [J].

Gulbins, E ;

Grassmé, H .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2002, 1585 (2-3) :139-145

← 1 2 3 4 5 6 7 8 9 →